Prodotti competitors / Area HIV
EU - EC Decision for ViiV's Triumeq PD for paediatric HIV patients
![Immagine News](/media/l4el5htd/cat-2.jpg?anchor=center&mode=crop&width=722&height=442)
ViiV Healthcare has announced that the European Commission has granted its Decision for Triumeq PD, a dispersible tablet formulation of the fixed dose combination of abacavir, dolutegravir and lamivudine for the treatment of paediatric patients weighing 14 kg to <25 kg with human immunodeficiency virus type 1 (HIV-1). This authorisation includes the label extension of Triumeq tablet, lowering the minimum weight that a child with HIV-1 can be prescribed this medicine from 40 kg to 25 kg.
Grazie per il tuo feedback!